Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shilpa Medicare Limited (SHILPAMED.NS)
INR645.75
+21.50 (+3.44%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Shilpa House 584135
Raichur, IN
Raichur, IN
CEO
Vishnukanth Chaturbhuj Bhutada
Website
vbshilpa.com
IPO
2009-12-03
ISIN INE790G01031
Also trades on
Bombay Stock Exchange · SHILPAMED.BO (INR)
National Stock Exchange of India · SHILPAMED.NS (INR)
Description
Shilpa Medicare Limited, including its various subsidiaries, manufactures and distributes a range of active pharmaceutical ingredients (APIs), intermediate compounds, and finished drug formulations. Operating across India, the United States, Europe, and other international markets, their product lineup encompasses both oncology and non-oncology APIs. The company also innovates with new drug delivery systems, biological products such as peptides, and specialized chemicals. Furthermore, Shilpa Medicare provides contract manufacturing services for diverse dosage forms, including tablets, capsules, liquid and lyophilized injectables, and sterile dry powder injectables. Beyond its pharmaceutical operations, the firm also participates in wind power generation. Founded in 1987, Shilpa Medicare Limited maintains its headquarters in Raichur, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR645.75
+21.50 (+3.44%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.22
Float Shares
96.96M
Free Float %
49.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.47% | +8.70% | +23.74% | +56.41% | +45.97% | +59.47% | +15.06% | +318.83% | +96.04% | +127.27% | +1,479.73% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
645.75
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
6.17
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+19.6% ★ Q1'26: +32.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+209.5% ★ Q1'26: +644.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+11.0% Q1'26: +8.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+20.5% ★ Q1'26: +20.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.1% ★ Q1'26: +9.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.4% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.52× Q1'26: 1.38× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.48B
est: 5.77B (-5.1%)
|
6.14B
est: 6.04B (+1.7%)
|
6.38B
est: 7.16B (-10.9%)
|
7.30B
est: 7.75B (-5.8%)
|
7.49B
est: 7.66B (-2.2%)
|
7.01B
est: 7.30B (-4.0%)
|
8.99B
est: 8.15B (+10.3%)
|
9.00B
est: 9.15B (-1.6%)
|
11.40B
est: 10.73B (+6.3%)
|
10.43B
est: 12.30B (-15.1%)
|
11.53B
est: 13.21B (-12.7%)
|
12.86B
est: 13.50B (-4.7%)
|
15.06B
15.06B – 15.06B
+11.6% YoY
|
16.94B
16.94B – 16.94B
+12.5% YoY
|
19.23B
19.23B – 19.23B
+13.5% YoY
|
22.81B
22.81B – 22.81B
+18.6% YoY
|
26.91B
26.91B – 26.91B
+18.0% YoY
|
| EBITDA |
1.22B
est: 1.23B (-0.4%)
|
1.33B
est: 1.22B (+9.2%)
|
1.68B
est: 1.59B (+5.3%)
|
1.87B
est: 1.82B (+2.9%)
|
1.83B
est: 1.96B (-6.5%)
|
1.81B
est: 1.91B (-5.3%)
|
2.37B
est: 2.46B (-3.7%)
|
2.73B
est: 1.94B (+40.3%)
|
2.23B
est: 2.28B (-2.1%)
|
1.13B
est: 4.23B (-73.2%)
|
2.46B
est: 2.81B (-12.3%)
|
3.11B
est: 2.87B (+8.4%)
|
3.20B
3.20B – 3.20B
+11.6% YoY
|
3.60B
3.60B – 3.60B
+12.5% YoY
|
4.09B
4.09B – 4.09B
+13.5% YoY
|
4.85B
4.85B – 4.85B
+18.6% YoY
|
5.72B
5.72B – 5.72B
+18.0% YoY
|
| EBIT |
989.76M
est: 761.39M (+30.0%)
|
1.12B
est: 996.62M (+12.3%)
|
1.44B
est: 1.27B (+14.0%)
|
1.49B
est: 1.50B (-0.3%)
|
1.39B
est: 1.25B (+11.1%)
|
1.39B
est: 1.10B (+26.3%)
|
1.93B
est: 1.04B (+85.2%)
|
2.19B
est: 1.21B (+81.2%)
|
1.43B
est: 1.41B (+1.2%)
|
179.75M
est: 3.18B (-94.4%)
|
1.38B
est: 1.74B (-20.7%)
|
1.98B
est: 1.78B (+11.2%)
|
1.99B
1.99B – 1.99B
+11.6% YoY
|
2.23B
2.23B – 2.23B
+12.5% YoY
|
2.54B
2.54B – 2.54B
+13.5% YoY
|
3.01B
3.01B – 3.01B
+18.6% YoY
|
3.55B
3.55B – 3.55B
+18.0% YoY
|
| Net Income |
756.69M
est: 2.17B (-65.2%)
|
736.91M
est: 789.43M (-6.7%)
|
1.08B
est: 888.69M (+21.9%)
|
1.08B
est: 1.17B (-8.3%)
|
1.05B
est: 1.06B (-1.2%)
|
1.12B
est: 1.01B (+10.8%)
|
1.56B
est: 1.24B (+26.1%)
|
1.48B
est: 1.54B (-4.2%)
|
606.62M
est: 652.44M (-7.0%)
|
-325.33M
est: 2.89B (-111.3%)
|
318.74M
est: 2.22B (-85.6%)
|
782.93M
est: 1.22B (-35.7%)
|
2.07B
2.07B – 2.07B
+70.4% YoY
|
2.52B
2.52B – 2.52B
+21.6% YoY
|
3.03B
3.03B – 3.03B
+20.1% YoY
|
3.47B
3.47B – 3.47B
+14.5% YoY
|
4.44B
4.44B – 4.44B
+28.1% YoY
|
| SGA |
91.45M
est: 1.22B (-92.5%)
|
86.02M
est: 1.08B (-92.0%)
|
119.43M
est: 1.36B (-91.2%)
|
107.88M
est: 1.47B (-92.6%)
|
129.50M
est: 1.75B (-92.6%)
|
198.27M
est: 1.96B (-89.9%)
|
606.04M
est: 2.71B (-77.6%)
|
476.44M
est: 1.93B (-75.3%)
|
2.82B
est: 2.26B (+24.8%)
|
2.97B
est: 5.83B (-49.0%)
|
3.02B
est: 2.79B (+8.6%)
|
2.66B
est: 2.85B (-6.5%)
|
3.18B
3.18B – 3.18B
+11.6% YoY
|
3.57B
3.57B – 3.57B
+12.5% YoY
|
4.06B
4.06B – 4.06B
+13.5% YoY
|
4.81B
4.81B – 4.81B
+18.6% YoY
|
5.68B
5.68B – 5.68B
+18.0% YoY
|
| EPS |
5.34
est: 11.16 (-52.2%)
|
4.80
est: 10.24 (-53.1%)
|
6.80
est: 6.03 (+12.7%)
|
6.91
est: 7.18 (-3.8%)
|
6.54
est: 6.78 (-3.7%)
|
6.89
est: 6.75 (+2.0%)
|
9.58
est: 11.85 (-19.2%)
|
9.07
est: 7.92 (+14.5%)
|
3.63
est: 3.35 (+8.4%)
|
-1.88
est: 7.05 (-126.6%)
|
1.84
est: 11.40 (-83.9%)
|
4.02
est: 6.25 (-35.7%)
|
10.65
10.65 – 10.65
+70.4% YoY
|
12.95
12.95 – 12.95
+21.6% YoY
|
15.55
15.55 – 15.55
+20.1% YoY
|
17.80
17.80 – 17.80
+14.5% YoY
|
22.80
22.80 – 22.80
+28.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-25 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.09B
OE per share TTM
10.69
Owner's Yield
2.09%
Maintenance CapEx ratio
290.85%
Maint CapEx / Avg PPE
132.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.68M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 120.2K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 53.3K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 5.93M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 85.3K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 6.76M | 0.05% |
| 7 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 9.5K | 0.22% |
| 8 | Vanguard Total World Stock ETF VT | 0.00% | 345.1K | 0.06% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 28.7K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 15.4K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
3.13M
Shares Outstanding
195.58M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vishnukanth Chaturbhuj Bhutada | MD & Director | 35M | male |
| Sharath Reddy Kalakota M.Pharma | Vice President of Projects & Operations and Whole-time Director | 18M | male |
| Ritu Tiwary | Company Secretary & Compliance Officer | 5M | female |
| Monish Shah | Head of Investor Relations | — | male |
| Pramod Kumar | Senior Vice President of Technical | — | — |
| Alpesh Maheshkumar Dalal | Chief Financial Officer | — | male |
| V. Narasimha Rao | Chief Human Resource Officer | — | male |
| Vinay Konaje | Business Head of Biologics | — | male |
| Rajyashri Karur Ramakrishnan | Chief Scientific Officer of Biologicals | — | female |
| Jayant Karajgi | Chief Operating Officer of Formulations | — | — |
| K. H. Honneshaiah | Head Operation of API | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SHILPAMED.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
